%A Amrutha, Madai %A Bifi, Joy %A Anoop, Thyvalappil %A Ajayakumar, Sreenivasan %A Radhakrishnan, K %A Rajiv, Sridharan %T Topical 0.1% adapalene gel versus 0.1% adapalene and 2.5% benzoyl peroxide combination gel in the treatment of mild-to-moderate acne vulgaris: An open-label randomized controlled pilot study %9 Original Article %D 2021 %J Indian Journal of Drugs in Dermatology %R 10.4103/ijdd.ijdd_29_20 %P 20-23 %V 7 %N 1 %U https://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=20;epage=23;aulast=Amrutha %8 January 1, 2021 %X Introduction: The combination of adapalene (ADA) benzoyl peroxide (BPO) offers a safe and effective alternative avoiding long-term antibiotic use in the management of acne vulgaris. Aims: The aim of this study was is to compare the clinical efficacy and tolerability of 0.1% ADA with combination of 0.1% ADA and 2.5% BPO in the treatment of mild-to-moderate acne vulgaris. Methods: All patients were instructed to apply the given topical medications to whole face, excluding lips and eyelids, once a day at night after washing and moistening the facial skin. Follow-up was done once every 4 weeks up to 12 weeks from the start of treatment. Efficacy of treatment arms was assessed by 4 parameters, namely percentage change of total lesion counts (TLCs), Acne severity index, success rate, and response rate. Statistical analysis was performed using the SPSS software version 16.0. Data were analyzed using the Chi-square test, Fisher's exact test, and Mann–Whitney U test. P < 0.05 was considered to indicate statistical significance. Results: Thirty-eight patients were in Group A (ADA-BPO) and 38 patients in Group B (ADA alone). At the end of 12 weeks, Group A had significantly less TLC as well as significant percentage change in total lesions than Group B. Group A was significantly better than Group B in TLC response rate also. Conclusions: The combination gel of 0.1% ADA and 2.5% BPO was superior to 0.1% ADA gel in terms of efficacy. Tolerability was comparable for both the drugs. %0 Journal Article %I Wolters Kluwer Medknow Publications %@ 2455-3972